Introduction
============

Of amphetamines and their related compounds, *d*-methamphetamine (METH) is one of the most powerful drugs of abuse recognized worldwide on the basis of an increasing number of health and social problems, both acute and chronic ([@b60-dti-1-2006-019]). In Japan, the third epidemic of METH abuse among the population is in progress ([@b94-dti-1-2006-019]), and about 18000 persons were arrested in 2004 for illegal drug abuse. The U.S. National Survey on Drug Use and Health estimated in 2004 that 1.4 million Americans aged 12 or older had used METH in the past year ([@b63-dti-1-2006-019]). The direct CNS effects of METH include increased wakefulness, increased respiration, enhanced body movements, hyperthermia, euphoria, and decreased appetite, as well as the following psychiatric sequelae: confusion, anxiety, paranoia, delirium, increased agitation, and aggressiveness ([@b62-dti-1-2006-019]). Recently, evidence has accumulated that METH can cause neurodegeneration in the brain ([@b15-dti-1-2006-019]; [@b43-dti-1-2006-019]; [@b13-dti-1-2006-019]). In addition, increased infectious diseases such as HIV and hepatitis B and C are likely to be consequences of increased METH abusers through sharing contaminated syringes ([@b69-dti-1-2006-019]). At present, however, there are no effective medications for the treatment of METH abuse ([@b41-dti-1-2006-019]).

The molecular basis of amphetamine action has been investigated. METH targets in subcellular components include the cocaine-sensitive dopamine transporter (DAT) located in presynaptic plasma membranes, the vesicular monoamine transporter-2 (VMAT-2) located in vesicular membranes, and the monoamine oxidase (MAO) enzyme located in mitochondrial outer membranes ([@b80-dti-1-2006-019]). The direct action of METH on DAT reverses dopamine transport, resulting in enhanced release of dopamine from presynaptic terminals into extracellular space ([@b84-dti-1-2006-019]; [@b39-dti-1-2006-019]; Khoshbouei et al. 2003). METH also enters the presynaptic neurons via lipophilic diffusion and through DAT as a structural analogue of dopamine ([@b102-dti-1-2006-019], [@b103-dti-1-2006-019]), thereby allowing the drug to enter synaptic vesicles through VMAT-2 and/or by diffusion. The resulting METH-induced disruption of vesicular pH produces enhanced release of dopamine from the vesicles through VMAT-2 ([@b84-dti-1-2006-019]; [@b39-dti-1-2006-019]). Once inside the presynaptic terminals, METH inhibits (i) VMAT-2; resulting in a decrease in vesicular dopamine uptake ([@b10-dti-1-2006-019]; [@b93-dti-1-2006-019]), and (ii) MAO, which catalyzes the oxidative deamination of monoamines, resulting in increased levels of monoamines such as dopamine and serotonin (5-hydroxytryptamine, 5-HT) and a decrease in their metabolites ([@b23-dti-1-2006-019]; [@b17-dti-1-2006-019]). Overall, the actions of METH on these three target proteins result in the massive outflow of dopamine from the presynaptic terminal into the synaptic cleft ([@b50-dti-1-2006-019]). The activation of dopamine receptors by aberrant levels of released dopamine in mesolimbic and mesocortical areas is closely related to METH-induced abnormal behavior and the rewarding property of the drug in rodents and humans ([@b77-dti-1-2006-019]; [@b80-dti-1-2006-019]; [@b81-dti-1-2006-019]; [@b27-dti-1-2006-019]; [@b21-dti-1-2006-019]).

Pre-clinical investigations suggest that DAT blockers such as vanoxerine (also known as GBR 12909) are effective for the prevention of cocaine effects such as cocaine-self administration and cocaine-induced increases in extracellular dopamine levels, because cocaine exerts its effects predominantly through an interaction with DAT ([@b29-dti-1-2006-019]). Pre-clinical evaluation of vanoxerine as a potential medication for METH addiction is also in progress ([@b7-dti-1-2006-019]). Alternatively, mechanism(s) other than DAT have been proposed for METH action in transgenic studies ([@b78-dti-1-2006-019]; [@b12-dti-1-2006-019]), because METH targets are multiple ([@b80-dti-1-2006-019]).

In the recent literature, some attempts have been made to find an effective treatment for METH abuse through one of the three targets listed above. This review describes current insights into the pharmacology of MAO inhibitors from the behavior of rodents administered with various doses of single and repeated METH, since relatively moderate and high doses of single and repeated METH administration in rodents serve as an animal model for METH abuse in humans (described below). Although amphetamines inhibit MAO reversibly, a role for MAO inhibition in amphetamine-induced behaviors has not brought much scientific interest since amphetamine-induced MAO inhibition is weak ([@b57-dti-1-2006-019]; [@b58-dti-1-2006-019]). However, recent evidence that METH (or *d*-amphetamine) in combination with MAO inhibitors produces unique behavioral effects, and implicates a role for MAO inhibitors in the protection against and improvement of METH abuse, especially, through the actions on the striatal serotonin system.

METH-Treated Rodents as Animal Models of METH Abuse
===================================================

The use of naïve rodents administered with single or repeated METH serves as an animal model for METH abuse in humans, since animal models show abnormal behavior such as increased motor activity ([@b1-dti-1-2006-019]; [@b44-dti-1-2006-019], [@b45-dti-1-2006-019]), repetitive and compulsive behavior called stereotypy ([@b64-dti-1-2006-019]; [@b50-dti-1-2006-019]; [@b1-dti-1-2006-019]; [@b86-dti-1-2006-019], [@b87-dti-1-2006-019]), self-injurious behavior ([@b32-dti-1-2006-019]; [@b59-dti-1-2006-019]), and rewarding properties ([@b71-dti-1-2006-019]; [@b40-dti-1-2006-019]; [@b47-dti-1-2006-019]), which resemble human symptoms of amphetamine psychosis ([@b72-dti-1-2006-019]; [@b31-dti-1-2006-019]; [@b96-dti-1-2006-019]). In addition to the effects of METH listed above, repeated administration of METH also induces a progressive augmentation of locomotor activity in response to treatment, a phenomenon referred to as behavioral sensitization ([@b70-dti-1-2006-019]; [@b83-dti-1-2006-019]; [@b65-dti-1-2006-019]; [@b34-dti-1-2006-019]; [@b33-dti-1-2006-019]; [@b35-dti-1-2006-019]; [@b44-dti-1-2006-019], [@b46-dti-1-2006-019]; [@b66-dti-1-2006-019]). The progressive augmentation of locomotor activity in response to repeated METH in rodents resembles the METH-induced psychiatric symptoms which show progressive quantitative alteration in METH addicts ([@b19-dti-1-2006-019]; [@b77-dti-1-2006-019]; [@b35-dti-1-2006-019]; [@b94-dti-1-2006-019]).

MAO, MAO Inhibitors, and Amphetamines
=====================================

In mammals, the MAO enzyme exists in two isoforms, termed MAO-A and MAO-B, which differ in substrate specificity ([@b38-dti-1-2006-019]; [@b61-dti-1-2006-019]) and have been identified as separate gene products ([@b82-dti-1-2006-019]). Selective and non-selective MAO inhibitors have been developed for pre-clinical and clinical purposes, especially as treatments for major depression and Parkinson's disease ([@b24-dti-1-2006-019]; [@b97-dti-1-2006-019]; [@b68-dti-1-2006-019]; [@b3-dti-1-2006-019]). The first MAO inhibitor to be discovered was the hydrazine derivative iproniazid, which was originally developed for the treatment of tuberculosis. Iproniazid and the related compounds are highly toxic to the liver when taken excess ([@b76-dti-1-2006-019]), resulting in the withdrawal of many hydrazine derivatives from the clinic. Then, the propargyl compounds were developed as MAO inhibitors with less undesirable side-effects ([@b85-dti-1-2006-019]). Among them, pargyline (*N*-methyl-*N*-2-propynylbenzylamine) and clorgyline (*N*-methyl-*N*-propargyl-3-(2, 4-dichlorophenoxy) propylamine) were reported to be irreversible inhibitors of MAO-A/B (non-selective) and MAO-A, respectively. Selective irreversible MAO-B inhibitors were also developed ([@b48-dti-1-2006-019]). One of them is selegiline (*N*, α-dimethyl-*N*-2-propynylphenethylamine; also know as *l*-deprenyl), which is a propargyl derivative of *l*-amphetamine.

Besides being potent monoamine releasing agents, amphetamines are also relatively potent, non-selective MAO inhibitors ([@b80-dti-1-2006-019]), while the inhibition is weak compared with the actions of synthetic MAO inhibitors ([@b57-dti-1-2006-019]; [@b58-dti-1-2006-019]).

While a valuable review highlights the advantages of MAO inhibitors ([@b101-dti-1-2006-019]), these propargyl compounds have received little attention in the literature in recent years because of (1) the side effects associated with this drug class, including possible hypertensive crisis, (2) the development of new and more specific types of agents for the treatment of mental diseases and, (3) the complex mechanism of action of MAO inhibitors, that are at least partially unresolved.

As for the clinical use of psychostimulant-MAO inhibitor combinations, amphetamine and MAO inhibitor combination therapy has been used to augment antidepressant treatment ([@b22-dti-1-2006-019]). Other clinical trials of amphetamine and MAO inhibitor combination appear to be highly restricted because of the lack of therapeutic benefits. In the animal experiments, however, the effects of clorgyline, selegiline, and pargyline on METH-induced behavior have been well documented.

Modification of METH Action by Clorgyline
=========================================

As shown in [Table 1](#t1-dti-1-2006-019){ref-type="table"}, clorgyline has no effect on spontaneous locomotor activity in naïve mice and rats ([Table 1](#t1-dti-1-2006-019){ref-type="table"}). However, when co-administered with METH, clorgyline exerts significant inhibitory effects on METH (1 mg/kg, i.p.)-induced hyperlocomotion after single and repeated (5 days) clorgyline administration ([@b45-dti-1-2006-019]). The effect of clorgyline on METH-induced behaviors lasts up to 40 min after METH challenge, suggesting that the development of METH-induced hyperlocomotion was effectively inhibited by clorgyline pretreatment ([@b45-dti-1-2006-019]). It should be noted that no enhanced stereotypic behavior including "mouthing" behavior in parallel with the decrease in hyperlocomotion after METH in mice pretreated with clorgyline was observed in terms of the rearing index ([@b45-dti-1-2006-019]). This effect was not observed with selegiline ([@b45-dti-1-2006-019]).

In this study, the association between the inhibitory action of clorgyline and MAO-A activity in the brain was simultaneously investigated. For this purpose, the activity of monoaminergic transmission was evaluated in terms of apparent mono-amine turnover. With respect to 5-HT metabolism, the ratio of 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of 5-HT, to 5-HT is a good index of apparent 5-HT turnover ([@b16-dti-1-2006-019]; [@b92-dti-1-2006-019]). 5-HT turnover was significantly increased in the regions of the striatum and nucleus accumbens after single METH administration due to a significant decrease in 5-HT levels ([@b44-dti-1-2006-019]). Clorgyline pretreatment, in turn, significantly increased and decreased 5-HT and 5-HIAA contents, respectively, by inhibiting MAO-A, resulting in a significant decrease in the 5-HT turnover index in the striatum and nucleus accumbens ([@b45-dti-1-2006-019]). This effect of clorgyline on 5-HT turnover is closely correlated with the drug's inhibitory action on METH-induced hyperlocomotion, evaluated by ANOVA analysis ([@b45-dti-1-2006-019]). This finding suggests that the improvement of METH-induced abnormal 5-HT turnover in the striatal region by clorgyline treatment may play a role in the suppression of METH-induced increase in motor activity. Since selegiline had no effect on 5-HT turnover *in vivo*, METH-induced hyperlocomotion and 5-HT turnover were not affected by selegiline pretreatment ([@b45-dti-1-2006-019]; [Table 1](#t1-dti-1-2006-019){ref-type="table"}).

Clorgyline action on METH-induced hyperlocomotion in mice ([@b45-dti-1-2006-019]) appears paradoxical, because clorgyline and METH were assumed to inhibit MAO-A activity additively, presumably resulting in enhanced METH toxicity (i.e. hypermotility) with clorgyline pretreatment. Indeed, for apparent dopamine turnover, an additive inhibition of the ratio of 3, 4-dihydroxyhen-ylacetic acid (DOPAC), a metabolite of dopamine, to dopamine by single METH administration after clorgyline pretreatment was observed in the regions of the striatum and nucleus accumbens in mice ([@b45-dti-1-2006-019]).

In light of these findings, why did the 5-HT content selectively decrease in the regions of the striatum and nucleus accumbens in mice after a relatively moderate dose of METH (1 mg/kg)? A depletion effect similar to this is often interpreted as evidence that the neurotoxic dosage of METH induces neurodegeneration in the terminals of monoaminergic neurons. In the rat brain striatum, neurotoxic METH destroys the terminal arbors of fine 5-HTergic axons that arise from the dorsal raphe nucleus, resulting in the acute depletion of 5-HT from the axons ([@b4-dti-1-2006-019]; Brown and Molliver, 2000). Similar neurodegeneration is observed in the dopaminergic axons of rats ([@b74-dti-1-2006-019], [@b75-dti-1-2006-019]; [@b99-dti-1-2006-019]), with a significant decrease in the striatal dopamine content ([@b9-dti-1-2006-019]). Neurotoxic dosages of METH in mice (four injections of 15 mg/kg METH every 2 h or a single administration with 30 mg/kg) have been shown to produce a significant decrease in the striatal contents of dopamine and 5-HT ([@b25-dti-1-2006-019]), similar to the observations in rats. Unfortunately, the possible neurodegenerative effects of METH at a moderate dose (1 mg/kg) on the striatal neuronal system in mice has not yet been studied.

Provided that monoaminergic axons in the striatum express properties that determine which are relatively vulnerable to METH at even moderate doses, there exists an obvious difference between dopamine and 5-HT fibers which result in the METH vulnerability. Since there is evidence of 10--30-fold higher content of dopamine than 5-HT in the mouse striatum ([@b44-dti-1-2006-019], [@b45-dti-1-2006-019], [@b47-dti-1-2006-019]), the density of dopamine-containing fibers might be higher than that of 5-HT-containing fibers, provided that the percentages of synapses occupied by dopamine and 5-HT present in the brain are identical ([@b49-dti-1-2006-019]). It is possible that the low density of striatal 5-HT fibers can be damaged more seriously than the dopamine fibers by METH at moderate doses. Striatal 5-HT neurotransmission is suggested to play a crucial role in the regulation of METH-induced hyperlocomotion in mice ([@b45-dti-1-2006-019]). Therefore, it is possible that MAO-A inhibition increases the content of 5-HT, resulting in a significant improvement in 5-HT neurotransmission which protects against METH-induced hyperlocomotion via the activation of 5-HT turnover.

Several investigations have shown that the development of sensitization to the locomotor stimulating effect of METH in rodents can be blocked effectively by pharmacological agents such as a protein synthesis inhibitor cycloheximide, nitric oxide synthase inhibitors *N*^G^-nitro-L-arginine and 7-nitroindazole, and a benzodiazepine clonazepam administered prior to, or simultaneously with METH (1 mg/kg once per day for 5--10 consecutive days or 2 mg/kg once per day, 5 times at intervals of 3--4 days) ([@b83-dti-1-2006-019]; [@b65-dti-1-2006-019]; [@b34-dti-1-2006-019]; [@b33-dti-1-2006-019]). Unfortunately, a protocol involving agent pretreatment or co-treatment is not easily applied to human METH addictions. To overcome this, we applied a modified treatment protocol to mice which have already acquired behavioral sensitization to METH (1 mg/kg, i.p. once per day for 5 consecutive days). During the drug-free period (4 days) after the repeated METH administration, the mice were treated with 1 mg/kg of clorgyline once per day. This treatment successfully blocked the expression of behavioral sensitization to METH ([Table 1](#t1-dti-1-2006-019){ref-type="table"}; [@b46-dti-1-2006-019]).

It is suggested that behavioral sensitization may have some common properties with learning and memory ([@b55-dti-1-2006-019]); therefore, the cerebral cortex is one region of interest. After the METH challenge, significantly enhanced dopamine metabolism (i.e. increased overall dopamine turnover, the ratio of homovanillic acid (HVA) to dopamine) was observed in the cerebral cortex of METH-sensitized mice compared with non-sensitized animals ([@b46-dti-1-2006-019]). In particular, cerebral cortical dopamine metabolism increased approximately 3-fold in sensitized mice treated with repeated clorgyline compared with mice without clorgyline treatment. It is likely that brain dopamine in mice, which is not metabolized by MAO-A after repeated clorgyline treatment ([@b45-dti-1-2006-019]) was, in turn, exposed to catechol-*O*-methyltransferase (COMT), another dopamine metabolizing enzyme. In the cerebral cortex, dopamine metabolism is more sensitive to COMT than that in the striatum or hypothalamus ([@b28-dti-1-2006-019]), or cerebral cortical MAO activity is lower than in other regions. Therefore, dopamine released in the cerebral cortex by a single METH challenge was metabolized largely by COMT after clorgyline treatment, resulting in inhibition of the expression of behavioral sensitization to METH. It is of interest to note the possible relationship between the activities of MAO-A and COMT, influenced by each other, in the brain; however, to our knowledge, there is no direct evidence of molecular interaction between the two enzymes. Clorgyline exhibits no behavioral sensitization *per se* ([Table 1](#t1-dti-1-2006-019){ref-type="table"}).

In rats, [@b79-dti-1-2006-019] reported that clorgyline (4 mg/kg) pretreatment significantly reduced locomotion (increased crossover plus rearing) during the first 1-h interval after the amphetamine challenge (0.25 and 2.5 mg/kg) in parallel with a significant increase in the total period of the observed stereotypy ([Table 1](#t1-dti-1-2006-019){ref-type="table"}). This effect is interpreted by experimental evidence that MAO-A inhibition by clorgyline increases the extracellular dopamine concentration in the nucleus accumbens, assessed by *in vivo* microdialysis. In contrast, no change in the intensity of METH (10 mg/kg)-induced stereotypy was observed in rats pretreated with clorgyline (0.1--10 mg) ([Table 1](#t1-dti-1-2006-019){ref-type="table"}; [@b86-dti-1-2006-019]). In mice, the lowest dose of clorgyline tested (0.1 mg/kg) significantly increased and decreased hyperlocomotion and stereotypy, respectively, during the first 20-min interval at which the mice showed a submaximal intensity of stereotypy ([@b86-dti-1-2006-019]). However, clorgyline pretreatment (1 and 10 mg/kg) did not significantly alter horizontal hyperlocomotion in mice during the first 20-min interval after METH challenge (10 mg/kg) compared with the mice pretreated with vehicle (saline). The molecular action of the clorgyline is likely to be independent of MAO-A because (1) change in the intensity of METH-induced stereotypy was not correlated with the change in the striatal monoamine turnover during the first 20-min interval ([@b87-dti-1-2006-019]) and, (2) the clorgyline (0.1 mg/kg)-induced shift in the METH response was not correlated with the degree of MAO-A inhibition estimated by apparent monoamine turnover ([@b86-dti-1-2006-019]).

Possible interactions of clorgyline with sigma receptors ([@b36-dti-1-2006-019]; [@b37-dti-1-2006-019]), imidazoline I~2~ receptors ([@b2-dti-1-2006-019]; [@b56-dti-1-2006-019]), and/or MAO inhibitor-displaceable quinpirole binding sites ([@b14-dti-1-2006-019]) should not be neglected to understand the mode of action of clorgyline, since these binding sites are involved in psychiatric disorders ([@b18-dti-1-2006-019]; [@b8-dti-1-2006-019]). Clorgyline displays high affinity for both MAO-A and sigma receptors with relatively identical affinities (IC~50~ value of 10 nM and 3 nM, respectively) ([@b17-dti-1-2006-019]; [@b37-dti-1-2006-019]), and clorgyline-sensitive sigma receptors are suggested to coexist with a subcellular fraction with MAO activity ([@b37-dti-1-2006-019]). Therefore, the doses of clorgyline used in the *in vivo* studies appear to fully activate the sigma receptors.

For the METH-induced rewarding property, clorgyline pretreatment (0.1--10 mg/kg) failed to block the METH (0.5 mg/kg)-induced increase in the conditioned place preference (CPP) index in mice ([Table 1](#t1-dti-1-2006-019){ref-type="table"}; [@b47-dti-1-2006-019]). The mono-amine turnover index (ratios of DOPAC to dopamine, HVA to dopamine, and 5-HIAA to 5-HT) in the striatum and nucleus accumbens was not different between mice conditioned with and without METH, indicating that the inhibitory effect of various doses of clorgyline on MAO activity was independent of METH (0.5 mg/kg) action. It should be noted that the saline/saline pairing groups pretreated with clorgyline at a dose of 1 mg/kg showed an increased CPP index, similar to the result from METH/saline pairing group ([@b47-dti-1-2006-019]). This might mean that the mice in the saline/saline pairing group entered and stayed in each CPP compartment independent of the given visual and texture cues on the testing day after the pretreatment with 1 mg/kg clorgyline.

Modification of METH Action by Selegiline
=========================================

Selegiline in appropriate doses exhibits amphetamine-like properties *per se*, such as increased motor activity, rewarding effect, and behavioral sensitization ([Table 1](#t1-dti-1-2006-019){ref-type="table"}), since selegiline is metabolized in part to *l*-METH and *l*-amphetamine ([@b73-dti-1-2006-019]; [@b20-dti-1-2006-019]; [@b51-dti-1-2006-019]; [@b26-dti-1-2006-019]; [@b5-dti-1-2006-019]). Because of the potential of the selegiline metabolites for abuse liability, it is likely that selegiline could enhance METH action when given in combination. Indeed, selegiline (20 mg/kg) induced the stereotyped head movement in rats, while the stereotypy was not observed when the rats were administered with 1--10 mg/kg of selegiline ([Table 1](#t1-dti-1-2006-019){ref-type="table"}; [@b91-dti-1-2006-019]). Selegiline in doses of 1--20 mg/kg had no effect on locomotion, CPP index, nor the number of conditioned avoidance responses ([@b91-dti-1-2006-019]).

Increased discriminative stimulus effects were reported using 3 and 5.6 mg/kg of selegiline in combination with *d*-amphetamine (1 mg/kg) compared with *d*-amphetamine alone in mice which have been trained under a 5-response, fixed ratio schedule of stimulus-shock termination or a 10-response, fixed ratio schedule of food presentation to discriminate between *d*-amphetamine (1 mg/kg) and saline in a two-lever, conditioning procedure ([Table 1](#t1-dti-1-2006-019){ref-type="table"}; [@b100-dti-1-2006-019]). Also, high doses of selegiline (17--30 mg/kg) produced full generalization to *d*-amphetamine ([@b100-dti-1-2006-019]). These observations as well as those of [@b91-dti-1-2006-019] suggest that the amphetamine-like properties can be observed when selegiline *l*-isomer) in high doses is treated.

Small doses of selegiline fail to induce any amphetamine-like hyperlocomotion ([@b89-dti-1-2006-019]). [@b90-dti-1-2006-019] reported that selegiline at small doses can decrease amphetamine-induced stereotypy in rats, without change in the index of dopamine turnover in the olfactory tubercle, compared with saline-pretreated animals. They suggest that the uptake of amphetamine might be reduced by pretreatment with selegiline, resulting in the decrease of stereotyped behavior; however, the same selegiline treatment protocol as that reported by [@b90-dti-1-2006-019] enhances striatal dopamine turnover ([@b104-dti-1-2006-019]). Therefore, the relationship between selegiline action on amphetamine-induced stereotypy and MAO-B activity needs to be clarified by further studies. Only one report shows the effect of selegiline on the lethal action of METH. Repeated administration with lower doses of selegiline (0.02 and 0.2 mg/kg) to mice treated with toxic METH dosage (10 mg/kg × 4 within one day, two-hour intervals) blocked the METH-induced increase in mortality ([Table 1](#t1-dti-1-2006-019){ref-type="table"}; [@b30-dti-1-2006-019]). This selegiline effect was not detected at 2 mg/kg, suggesting that the mode of action is MAO-B independent. Regarding this point, [@b52-dti-1-2006-019] reported that increased DAT expression was observed after chronic (21 days) treatment with selegiline (0.25 mg/kg). This might explain the results of [@b90-dti-1-2006-019] and of [@b30-dti-1-2006-019], since the increased DAT expression induces increased extracellular dopamine clearance in the brain. Molecular mechanism(s) of the enhanced DAT expression by selegiline are unclear, although selegiline has been shown to alter the expression of mRNA for a variety of proteins including tyrosine hydroxylase and L-aromatic amino acid decarboxylase ([@b95-dti-1-2006-019]; [@b54-dti-1-2006-019]).

In mice, stereotypy can be induced by METH at doses of 10 mg/kg by a single injection ([@b86-dti-1-2006-019]). When administered of mice with 20 mg/kg METH, the mice show self-injurious behavior ([@b59-dti-1-2006-019]). [@b86-dti-1-2006-019] reported that a wide range of selegiline (0.1--10 mg/kg) showed no enhancement of METH-induced stereotyped behavior nor a shift of the abnormal behavior from stereotypy to self-injurious behavior in mice, suggesting that 10 mg/kg of selegiline could not have an amphetamine (10 mg/kg)-like property after the systemic injection and following metabolism.

Modification of METH Action by Non-selective MAO Inhibitors
===========================================================

[@b53-dti-1-2006-019] reported that pretreatment of mice with 50 mg/kg of pargyline, a non-selective MAO inhibitor, had no effect on *d*-amphetamine-induced hyperlocomotion in mice ([Table 1](#t1-dti-1-2006-019){ref-type="table"}). However, treatment of rats with 10 mg/kg of pargyline increases locomotor activity *per se* ([Table 1](#t1-dti-1-2006-019){ref-type="table"}; [@b6-dti-1-2006-019]); this effect might be interpreted by evidence that MAO-A inhibition by clorgyline (and probably by pargyline at high doses) increases extracellular dopamine concentration in the nucleus accumbens ([@b79-dti-1-2006-019]). The possible effect of metabolites of pargyline (benzylamine, *N*-methylbenzylamine, and *N*-propargylbenzylamine) on spontaneous locomotion in rodents can not be ruled out, but no reports have not been published.

[@b3-dti-1-2006-019] reported the behavioral profile of a newly developed, mixed-reversible MAO-A/B inhibitor, SL25.1131, in mice. The agent can improve decreased dopaminergic tone in the striatum by inhibiting MAO-A and --B and locomotion disrupted by treatment with MPTP (1-methyl-4-pheny l--1,2,3,6-tetrahydropyridine). Mixed MAO inhibitors possess attractive potential properties for the treatment of METH abuse, since selective, irreversible MAO inhibitors can block METH (or *d*-amphetamine)-induced abnormal behavior in rodents ([Table 1](#t1-dti-1-2006-019){ref-type="table"}), although the mechanisms of action are complex.

Conclusions
===========

METH-induced motor activity, stereotypy, and sensitization are closely associated with monoaminergic transmission. Modification of MAO activity by MAO inhibitors can influence METH action. Although some pre-clinical studies cited in this review suggest the feasibility of MAO inhibitors for the treatment of METH abuse, careful attention should be directed to the potential risk similar to that reported in the treatment of depressive disorder. Based on the current research on the mechanisms of MAO inhibitors, they exhibit a putative 'novel' mode of action which is independent of MAO and might influence monoaminergic-related behavior, as well as 'classical' MAO inhibition. For pre-clinical studies of the exact mode of action of MAO inhibitors and the effects of the MAO inhibitors on METH-induced abnormal behavior, METH-induced abnormal behavior in rodents may serve as an appropriate animal model for METH abuse in humans.
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###### 

Effects of MAO inhibitors on behavior of naïve and METH (or *d*-amphetamine)-challenged rodents.

  Measurement                                         MAOI         Species, Dose and Injection Schedule    Effect[a](#tfn2-dti-1-2006-019){ref-type="table-fn"}   Reference
  --------------------------------------------------- ------------ --------------------------------------- ------------------------------------------------------ ---------------------------------------------
  Naïve                                                                                                                                                           
  Locomotion                                          Clorgyline   Rat, 4 mg/kg, ip x 1 d                  NC                                                     [@b79-dti-1-2006-019]
                                                      Clorgyline   Mouse, 1 mg/kg, sc x 1 d or 5 d         NC                                                     [@b45-dti-1-2006-019]
                                                      Selegiline   Rat, 0.25 mg/kg, sc x 42 d              NC                                                     [@b89-dti-1-2006-019]
                                                      Selegiline   Rat, 1--20 mg/kg, sc x 1 d              NC                                                     [@b91-dti-1-2006-019]
                                                      Selegiline   Rat, 10 mg/kg, ip x 1 d                 Increase                                               [@b67-dti-1-2006-019]
                                                      Selegiline   Rat, 10 mg/kg, ip x 1 d                 Increase                                               [@b88-dti-1-2006-019]
                                                      Selegiline   Mouse, 0.3 mg/kg, sc x 1 d or 5 d       NC                                                     [@b45-dti-1-2006-019]
                                                      Pargyline    Rat, 10 mg/kg, sc x 24 d                Increase                                               [@b6-dti-1-2006-019]
  Stereotypy                                          Selegiline   Rat, 1--10 mg/kg, sc x 1 d              ND                                                     [@b91-dti-1-2006-019]
                                                      Selegiline   Rat, 20 mg/kg, sc x 1 d                 Increase                                               [@b91-dti-1-2006-019]
  Behavioral sensitization                            Clorgyline   Mouse, 1 mg/kg, sc x 5 d                ND                                                     [@b46-dti-1-2006-019]
                                                      Selegiline   Rat, 10 mg/kg, ip x 8 d                 Increase                                               [@b88-dti-1-2006-019]
  CPP index                                           Clorgyline   Mouse, 0.1--10 mg/kg, sc x 6 d          Increase                                               [@b47-dti-1-2006-019]
                                                      Selegiline   Rat, 1--20 mg/kg, sc x 4 d              ND                                                     [@b91-dti-1-2006-019]
                                                      Selegiline   Mouse, 10 and 25 mg/kg, ip x 5 d        Increase                                               [@b98-dti-1-2006-019]
  \# of CAR                                           Selegiline   Rat, 1--20 mg/kg, sc x 5 d              ND                                                     [@b91-dti-1-2006-019]
  DSE[b](#tfn3-dti-1-2006-019){ref-type="table-fn"}   Selegiline   Rat, 10--30 mg/kg, ip x 1               Increase                                               [@b100-dti-1-2006-019]
  After METH (or *d*-Amphetamine) challenge                                                                                                                       
  Hyperlocomotion                                     Clorgyline   Rat, 4 mg/kg, ip x 1 d                  Decrease                                               [@b79-dti-1-2006-019]
                                                      Clorgyline   Mouse, 1 mg/kg, sc x 1 d or 5 d         Decrease                                               [@b45-dti-1-2006-019],[@b46-dti-1-2006-019]
                                                      Selegiline   Mouse, 0.3 mg/kg, sc x 1 d or 5 d       NC                                                     [@b45-dti-1-2006-019]
                                                      Pargyline    Mouse, 50 mg/kg, ip x 1 d               NC                                                     [@b53-dti-1-2006-019]
  Stereotypy                                          Clorgyline   Rat, 4 mg/kg, ip x 1 d                  Increase                                               [@b79-dti-1-2006-019]
                                                      Clorgyline   Rat, 0.1--10 mg/kg, sc x 1 d            NC                                                     [@b86-dti-1-2006-019]
                                                      Clorgyline   Mouse, 0.1 not 1--10 mg/kg, sc x 1 d    Decrease                                               [@b86-dti-1-2006-019]
                                                      Selegiline   Rat, 0.25--5 mg/kg, sc x 1 d            Decrease                                               [@b90-dti-1-2006-019]
                                                      Selegiline   Mouse, 0.1, 1 and 10 mg/kg, sc x 1 d    NC                                                     [@b86-dti-1-2006-019]
  Behavioral sensitization                            Clorgyline   Mouse, 1 mg/kg, sc x 5 d                Decrease                                               [@b46-dti-1-2006-019]
  CPP index                                           Clorgyline   Mouse, 0.1--10 mg/kg, sc x 6 d          NC                                                     [@b47-dti-1-2006-019]
  DSE[b](#tfn3-dti-1-2006-019){ref-type="table-fn"}   Selegiline   Rat, 3 and 5.6 mg/kg, ip x 1            Increase                                               [@b100-dti-1-2006-019]
  Mortality                                           Selegiline   Mouse, 2 mg/kg, sc, x 13 d              NC                                                     [@b30-dti-1-2006-019]
                                                      Selegiline   Mouse, 0.02 and 0.2 mg/kg, sc, x 13 d   Decrease                                               [@b30-dti-1-2006-019]

This table compares the published effects of MAO inhibitors (MAOI) on naïve and METH-treated mice. CAR: conditioned avoidance responses; CPP: conditioned place preference; DSE: discriminative stimulus effect; NC: no change; ND: not detected; ip: intraperitoneal injection; sc: subcutaneous injection. "Selegiline" means "*l*-isomer of selegiline" in this table.

Comparison between MAOI- and vehicle-pretreated subjects.

Mice were used after they were trained under a 5-response, fixed ratio schedule of stimulus-shock termination or a 10-response, fixed ratio schedule of food presentation to discriminate between *d*-amphetamine (1 mg/kg) and saline in a two-lever, conditioning procedure.
